Xarelto rivaroxaban regulatory update

The Scottish Medicines Consortium recommended the restricted use of Bayer's Xarelto rivaroxaban on the National Health Service (NHS) in Scotland to prevent stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with 1 or more risk factors, including congestive heart failure, hypertension, >=75 years old, diabetes, prior stroke or transient ischemic attack - its approved indication. The consortium recommended the use of Xarelto only in patients who have poor control in regards to international normalized ratio (INR) despite evidence that they are complying with a warfarin anticoagulant, and in patients who are allergic to or unable to tolerate warfarin anticoagulants. ...